Want to join the conversation?
$GILD said that FDA has granted priority review to the company's NDA for an investigational, once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved as Sovaldi in Dec. 2013 & velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 HCV infection.
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.
Trivago N.V. (TRVG) announced today that it will release its financial results for the first quarter for the period ended March 31, 2017 on Monday, May 15, 2017. On the same day, trivago N.V.`s management will conduct a webcast beginning at 2:00 PM CET / 8:00 AM Eastern Time. These items will be available in the Investor Relations section of the company`s website at http://ir.trivago.com.